Healthcare / BiotechnologyMCE
$2.73
+0.01 (+0.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-10.1M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$207M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-66.0%
↓Gross Margin
43.5%
↓Debt/Equity
1.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.8%
FCF CAGR
—
FCF margin
-10.0%
FCF / Net income
0.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $141.0M · net income $-100.3M · FCF $-14.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $141.0M | $141.0M | $130.0M | $201.6M | $158.4M |
| Net Income | $-100.3M | $-100.3M | $-31.8M | $-45.6M | $-23.1M |
| EBITDA | $-10.0M | $-10.0M | $17.0M | $29.0M | $13.7M |
| EPS | — | — | -0.42 | -0.60 | -0.34 |
| Gross Margin | 43.5% | 43.5% | 50.4% | 70.3% | 79.6% |
| Operating Margin | -4.1% | -4.1% | 4.5% | 1.5% | -2.3% |
| Net Margin | -71.1% | -71.1% | -24.4% | -22.6% | -14.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.70 | 1.70 | 1.01 | 0.88 | 0.72 |
| Current Ratio | 0.81 | 0.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-14.1M | $-14.1M | $-10.1M | $-7.4M | $-30.6M |
| Returns | |||||
| ROE | -66.0% | -66.0% | -12.6% | -15.7% | -6.9% |
| Valuation | |||||
| EV/EBITDA | — | — | 29.48 | 17.35 | 46.54 |
| P/B | 1.36 | 1.36 | 1.05 | 1.00 | 1.28 |
| Growth & Yield | |||||
| Revenue Growth | 8.5% | 8.5% | -35.5% | 27.3% | — |
| EPS Growth | — | — | 30.1% | -77.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.42 → n/d
Residual
+3.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.